Centene Inc. CNC reported
fourth-quarter 2018 adjusted earnings per share of $1.38, beating
the Zacks Consensus Estimate of $1.33 by 3.8%. Also, the bottom
line improved 42.3% year over year.
For the fourth quarter, total revenues jumped 29% to $16.6 billion
from the year-ago period, primarily aided by a solid Health
Insurance Marketplace business in 2018, purchase of Fidelis Care,
expansions and new programs across many states in 2018 and
reinstatement of the health insurer fee in 2018. However, this
upside was partially offset by lower pass-through payments from
California and the effect of removal of in-home support services
(IHSS) program from Californiaâs Medicaid contract. Moreover, the
top line surpassed the Zacks Consensus Estimate by nearly 2%.
Quarterly Operational Update
As of Dec 31, 2018, managed care membership came in at 14 million,
reflecting a 14.8% increase over the level on Dec 31, 2017.
Health Benefit Ratio (HBR) for the reported quarter was 86.8%
compared with 87.3% in the prior-year period. This contraction of
50 basis points (bps) is mainly due to membership growth in the
Health Insurance Marketplace business and the reinstatement of the
health insurer fee in 2018. However, this downside was partially
offset by the buyout of Fidelis Care.
Adjusted Selling, General & Administrative (SG&A) expense
ratio of 9.9% for the fourth quarter of 2018 compared with 10.5%
for the same period last year. This decline of 60 basis points year
over year is due to the impact of Fidelis Care acquisition.
However, the same was partially offset by growth in Health
Insurance Marketplace business and on account of the removal of
IHSS program from California's Medicaid contract.
Centene Corporation Price, Consensus and EPS Surprise
Centene Corporation Price, Consensus and EPS Surprise | Centene Corporation Quote
Financial Update
As of Dec 31, 2018, the company's cash and cash equivalents totaled
$5.3 billion, up 31.1 % from the figure at 2017 end.
As of Dec 31, 2018, total assets were up by 41.4% year over year to
$30.9 billion.
Centeneâs long-term debt summed $6.6 billion, up 41.6% year over
year.
For 2018, cash outflow from operations was $1.2 billion, down 17.1%
from 2017âs level.
Capital Deployment
On Dec 12, 2018, the companyâs board of directors announced a
two-for-one split of its common stock in the form of a 100% stock
dividend, payable Feb 6, 2019 to shareholders of record on Dec 24,
2018.
2019 Outlook
Following strong 2018 results, the company has issued an outlook
for 2019 earnings. It expects its total revenues to be in the band
of $70.3-$71.1 billion.
Adjusted EPS is forecast between $4.11 and $4.31.
The company projects its HBR to range from 86.5% to 87%.
In 2019, adjusted SG&A expense ratio is estimated between 9.3%
and 9.8%.
The company anticipates its shares outstanding in the range of
421.5-422.5 million.
Full-Year Highlights
For 2018, the company delivered an adjusted EPS of $7.08, up 40.8%
year over year.
Revenues for the full year came in at $60 billion, mirroring an
improvement of 24.3% year over year.
Health benefits ratio (HBR) for the full year stands at 85.9%
compared with 2017's tally of 87.3%.
The company reported adjusted SG&A expense ratio of 10.0% for
2018, up by 50 basis points from 9.5% for 2017.
Zacks Rank
Centene carries a Zacks Rank #3 (Hold). You can see the
complete list of todayâs Zacks #1 Rank (Strong Buy) stocks
here.
Upcoming Releases From Medical
Sector
Some better-ranked stocks from the medical sector are as
follows:
Molina Healthcare, Inc MOH is set to report fourth-quarter 2018
earnings performance on Feb 11. The stock has an Earnings ESP of
+2.89% and a Zacks Rank #1.
Endologix, Inc. ELGX is slated to announce fourth-quarter earnings
numbers on Feb 25. It has a Zacks Rank of 3 and an Earnings ESP of
+21.43%.
Tenet Healthcare Corporation THC has an Earnings ESP of +5.63%.
This company is a Zacks #3 Ranked player and is scheduled to
release fourth-quarter financial figures on Feb 25.
Zacks' Top 10 Stocks for
2019
In addition to the stocks discussed above, would you like to know
about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with
amazing regularity. In 2018, while the market dropped -5.2%, the
portfolio scored well into double-digits overall with individual
stocks rising as high as +61.5%. And from 2012-2017, while the
market boomed +126.3, Zacks' Top 10s reached an even more
sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free
report
Tenet Healthcare
Corporation (THC) : Free Stock Analysis Report
Endologix, Inc. (ELGX) :
Free Stock Analysis Report
To read this article on
Zacks.com click here.
Zacks Investment Research